BriaCell Phase 1/2a Trial Underway
March 16, 2017 at 06:30 AM EDT
BriaCell Therapeutics remains one of my favorite under-the-radar immuno-oncology names. Finally, the CEO just invested $1.5 million of his own money into the story and that alone should warrant investors attention.
